STANDARD BIOTOOLS INC. (LAB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 50M 100M 150M FY09: 25.4M FY10: 33.6M FY11: 42.9M FY12: 52.3M FY13: 71.2M FY14: 116.5M FY15: 114.7M FY16: 104.4M FY17: 101.9M FY18: 113M FY19: 117.2M FY20: 138.1M FY21: 130.6M FY22: 97.9M FY23: 106.3M FY24: 91M FY25: 85.3M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 25M 50M 75M FY16: 58.4M FY17: 52M FY18: 61.6M FY19: 64.3M FY22: 37.1M FY23: 50.5M FY24: 44.9M FY25: 42.5M FY16 FY17 FY18 FY19 FY22 FY23 FY24 FY25

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY09: -18M FY10: -14.6M FY11: -18.6M FY12: -18.1M FY13: -18.7M FY14: -51.8M FY15: -50.2M FY16: -73.2M FY17: -58.4M FY18: -48.2M FY19: -51.8M FY20: -51M FY21: -67.5M FY22: -116.2M FY23: -76.6M FY24: -127.5M FY25: -110.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-210M -140M -70M 0 70M 140M 210M FY09: -19.1M FY09: -19.1M FY10: -16.9M FY11: -22.5M FY12: -19M FY13: -16.5M FY14: -52.8M FY15: -53.3M FY16: -76M FY17: -60.5M FY18: -59M FY19: -64.8M FY20: -53M FY21: -59.2M FY22: -190.1M FY23: -74.7M FY24: -138.9M FY25: -74.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 25M 50M 75M FY11: 100K FY12: 300K FY13: 300K FY14: 300K FY15: 300K FY16: 46M FY17: 50M FY18: 51.3M FY19: 53M FY22: 60.9M FY23: 55.9M FY24: 46.1M FY25: 42.8M FY11 FY13 FY15 FY17 FY19 FY23 FY25

Operating Cash Flow Annual

-150M -100M -50M 0 50M 100M 150M FY09: -19.5M FY10: -11.5M FY11: -17.5M FY12: -17.5M FY13: -1.6M FY14: -22.6M FY15: -34.7M FY16: -39.1M FY17: -24.1M FY18: -25.2M FY19: -35.2M FY20: -15.4M FY21: -44.1M FY22: -89.4M FY23: -43.3M FY24: -143.5M FY25: -74.3M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-180M -120M -60M 0 60M 120M 180M FY09: -20.3M FY10: -13M FY11: -19.2M FY12: -19.9M FY13: -5M FY14: -30M FY15: -38.7M FY16: -44.2M FY17: -25.7M FY18: -25.6M FY19: -37.7M FY20: -28.1M FY21: -57.3M FY22: -93.2M FY23: -46.1M FY24: -151.8M FY25: -82.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 150M 300M 450M FY19: 66.8M FY20: 72M FY21: 75.8M FY22: 78.3M FY23: 79.2M FY24: 353.2M FY25: 381.6M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '10: -8.94 Q1 '11: -7.54 Q2 '11: -5.31 Q3 '11: -3.75 Q4 '11: -2.35 Q1 '12: -1.08 Q2 '12: -0.94 Q3 '12: -0.90 Q4 '12: -0.87 Q1 '13: -0.68 Q2 '13: -0.62 Q3 '13: -0.61 Q4 '13: -0.65 Q1 '14: -1.08 Q2 '14: -1.37 Q3 '14: -1.69 Q4 '14: -1.90 Q1 '15: -1.89 Q2 '15: -1.97 Q3 '15: -1.80 Q4 '15: -1.86 Q1 '16: -1.99 Q2 '16: -2.10 Q3 '16: -2.46 Q4 '16: -2.62 Q1 '17: -2.52 Q2 '17: -2.46 Q3 '17: -2.24 Q4 '17: -1.90 Q1 '18: -1.65 Q2 '18: -1.49 Q3 '18: -1.41 Q4 '18: -1.50 Q1 '19: -1.60 Q2 '19: -1.38 Q3 '19: -1.19 Q4 '19: -1.01 Q1 '20: -0.80 Q2 '20: -0.78 Q3 '20: -0.67 Q4 '20: -0.74 Q1 '21: -0.76 Q2 '21: -0.81 Q3 '21: -0.91 Q4 '21: -0.78 Q1 '22: -1.52 Q2 '22: -2.11 Q3 '22: -2.30 Q4 '22: -2.44 Q1 '23: -1.66 Q2 '23: -1.06 Q3 '23: -0.96 Q4 '23: -0.95 Q1 '24: -1.01 Q2 '24: -0.91 Q3 '24: -0.71 Q4 '24: -0.54 Q1 '25: -0.34 Q2 '25: -0.31 Q3 '25: -0.33 Q4 '25: -0.20 Q1 '26: 0.20 Q2 '26: 0.22 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.